Pharma R&D Annual Review 2022: Navigating Landscape
Source: Citeline
The 30th anniversary edition of this comprehensive annual review assesses industry tends by examining the pipeline by company, therapeutic area, disease target and drug type. This year, over 20,000 drugs are in the pipeline, an increase of 8.22% over 2021 and close to twice the rate over the previous 12 months.
access the E-Book!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
Citeline
This website uses cookies to ensure you get the best experience on our website. Learn more